Type: Subsidiary
On the web: http://www.osip.com

Fighting disease in small ways is what OSI Pharmaceuticals is all about. The company focuses on small molecule cures for diseases like cancer, allowing for treatment by pill rather than IV infusion. Its top seller Tarceva treats non-small cell lung cancer and pancreatic cancer and is in development for other indications as well. Partner Genentech co-promotes the drug in the US, and it is marketed internationally by Roche. OSI also has a pipeline of drug candidates focused on new anti-cancer compounds. UK subsidiary Prosidion manages the company's small-molecule patents for diabetes and obesity treatments. OSI was acquired by Japanese drugmaker Astellas Pharma for $4 billion in 2010.

Officers:
Chairman: Robert A. (Bob) Ingram
EVP, CFO, and Treasurer: Pierre Legault
Director Public Relations: Kim Wittig

Competitors:
AstraZeneca
Bristol-Myers Squibb
Genentech

© 2012 Hoover's, Inc. All rights reserved.